| Publication Abstract Display |
| Type: Published Abstract |
| Title: Safety and efficacy of cannabidiol in rheumatoid arthritis patients: A Phase 1B pilot randomized placebo controlled trial. |
| Authors: Ranganath V, Wilhalme H, Morris N, Brook J, Taylor M, Yang H, Kermani T, Aung T, Skaggs B, Elashoff D, Cooper Z |
| Year: 2024 |
| Publication: Arthritis Rheumatol |
| Volume: 76 Issue: Suppl 9 Pages: |
| Abstract:There is no cure for rheumatoid arthritis (RA) and remission rates vary greatly 10-60%; thus, there is an unmet need for safe adjunctive therapeutic agents to decrease inflammation and improve RA outcomes. The use of cannabidiol (CBD) in preclinical RA models have shown reductions in pain, disease severity, and inflammatory infiltrates. The objective of this pilot randomized controlled trial (RCT) was to examine the dose-dependent safety and efficacy CBD relative to placebo (PBO) in RA patients with moderate to severe disease activity. |